Lee, Sang Bae http://orcid.org/0000-0002-4031-8051
Garofano, Luciano http://orcid.org/0000-0001-8582-0865
Ko, Aram http://orcid.org/0000-0003-4997-3092
D’Angelo, Fulvio http://orcid.org/0000-0002-4940-4693
Frangaj, Brulinda
Sommer, Danika
Gan, Qiwen
Kim, KyeongJin http://orcid.org/0000-0001-6865-9141
Cardozo, Timothy http://orcid.org/0000-0002-0643-4497
Iavarone, Antonio http://orcid.org/0000-0002-0683-4634
Lasorella, Anna http://orcid.org/0000-0002-1839-5421
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2020R1C1C1014281, NRF-2021R1A5A8029876, NRF-2020R1C1C1004015, NRF-2021R1A5A2031612)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA178546, U54CA193313, R01CA179044, R01CA190891, R01CA101644, U54CA193313, R01CA131126)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 30 July 2021
Accepted: 13 March 2022
First Online: 19 April 2022
Competing interests
: A.L. and A.I. are inventors of a biomarker technology that has been licensed to QIAGEN. A.I. received sponsored research funding from AstraZeneca and Taiho Pharmaceutical and has served as a paid consultant/advisor to AIMEDBIO Inc. A.L. received sponsored research funding from Celgene. All other authors declare no competing interests.